Search

Search Constraints

You searched for: Record Type Journal Article Author/Creator Ho, Bao

Search Results

1. 68Ga‐PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. (24th January 2016)

2. 68Ga‐PSMA‐PET/CT staging prior to definitive radiation treatment for prostate cancer. Issue 4 (16th April 2018)

3. Delineating biochemical failure with 68Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. Issue 1 (January 2017)

4. Diagnostic accuracy of 68Ga‐prostate‐specific membrane antigen (PSMA) positron‐emission tomography (PET) and multiparametric (mp)MRI to detect intermediate‐grade intra‐prostatic prostate cancer using whole‐mount pathology: impact of the addition of 68Ga‐PSMA PET to mpMRI. (9th July 2019)

5. Diagnostic value of 68Ga‐DOTATATE PET‐CT imaging for staging of ER+/PR+ HER2‐ breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and 18F‐FDG PET‐CT in a prospective pilot trial. Issue 6 (21st October 2021)

6. Event‐free survival after radical prostatectomy according to prostate‐specific membrane antigen‐positron emission tomography and European Association of Urology biochemical recurrence risk groups. (12th July 2022)

8. Gallium‐68‐prostate‐specific membrane antigen (68Ga‐PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate‐ and high‐risk prostate cancer. (7th April 2019)

9. Prospective evaluation of 68Gallium‐prostate‐specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. (18th June 2016)